A Phase 1 interventional study of Tezepelumab and Placebo in Atopic Dermatitis and Healthy Volunteers, sponsored by Amgen. Completed. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-21.
Sponsored by Amgen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Dermatitis, Atopic by Amgen — none open to participants now, none under way, none of them phase 3. Dermatitis, Atopic · Amgen.
Among the 15 studies in Dermatitis, Atopic by Amgen, this one is the 13th largest by enrollment, is the only one that started in 2008, is one of 5 in phase 1, and was the 1st registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →None of the 15 studies in Dermatitis, Atopic by Amgen is open now. The open studies under Dermatitis, Atopic, anywhere →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 78 is close to the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 231 across the 15 interventional studies. Of the 15 that completed or were terminated, 10 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Dermatitis, Atopic by Amgen, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a single dose escalation study of tezepelumab (AMG 157) in healthy adults (Part A) and adults with moderate to severe atopic dermatitis (Part B). The purpose of the study is to evaluate the safety, tolerability, immunogenicity and pharmacokinetics of tezepelumab.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of tezepelumab administered subcutaneously or intravenously. The starting dose will be 2.1 mg tezepelumab.
Drug: Tezepelumab
Participants will receive matching placebo administered subcutaneously or intravenously.
Drug: Placebo
Administered by subcutaneous or intravenous injection
Also known as: AMG 157, Tezspire
Matching placebo administered by subcutaneous or intravenous injection.
Number of Participants With Adverse Events
Adverse events (AEs) include any untoward medical occurrence in a trial participant administered a study drug and does not necessarily have a causal relationship with this treatment. AEs include worsening of a pre-existing medical condition and laboratory value changes requiring therapy or adjustment in prior therapy. AEs were assessed for severity according to the Common Terminology Criteria for Adverse Events (CTCAE), Version 3, where Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = severe AE, Grade 4 = life-threatening AE and Grade 5 = death due to AE. Relationship to study treatment was determined by the investigator. A serious adverse event (SAE) is defined as an AE that met 1 or more of below criteria: * was fatal; * was life threatening; * required in-patient hospitalization or prolongation of existing hospitalization; * resulted in persistent or significant disability/incapacity; * was a congenital anomaly/birth defect; * other significant medical hazard.
Time frame: For Part A Tezepelumab/Placebo 2.1 mg, 7 mg, 21 mg, 70 mg, and 210 mg SC: 85 days. For Part A Tezepelumab/Placebo 420 mg SC, 210 mg IV, and 700 mg IV and Part B: 113 days
Number of Participants Who Developed Anti-tezepelumab Antibodies
All study samples (tezepelumab and placebo) were tested using an electrochemiluminescence (ECL) based immunoassay to detect and confirm the presence of antibodies capable of binding to tezepelumab. Samples identified as positive in the immunoassay were tested in a receptor-binding ECL-based assay to detect neutralizing or inhibitory effects toward tezepelumab. The number of participants with positive anti-tezepelumab binding antibodies / neutralizing antibodies at any time post-baseline with a negative or no result at baseline is reported.
Time frame: Blood samples for the measurement of antibodies were collected on Days 29, 57, 85, and (for cohorts who received 420 mg Tezepelumab/placebo SC or any IV dose) 113.
Part A: Time of Maximum Observed Concentration (Tmax) of Tezepelumab
The time at which the maximum concentration of tezepelumab was observed was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification of the assay was 10 ng/mL.
Time frame: Day 1 predose, 0.25, 0.5, and 1 hour after start of infusion (for IV cohorts only), 4, 8, 24, 48, 72 hours postdose and days 5, 6, 7, 11, 15, 22, 29, 43, 57, 71, 85, and (for cohorts who received 420 mg tezepelumab SC or any IV dose) 113.
Part A: Maximum Observed Concentration (Cmax) of Tezepelumab
The maximum observed serum concentration of tezepelumab was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification of the assay was 10 ng/mL.
Time frame: Day 1 predose, 0.25, 0.5, and 1 hour after start of infusion (for IV cohorts only), 4, 8, 24, 48, 72 hours postdose and days 5, 6, 7, 11, 15, 22, 29, 43, 57, 71, 85, and (for cohorts who received 420 mg tezepelumab SC or any IV dose) 113.
Part A: Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Tezepelumab
The PK parameter AUC0-t was estimated based on the serum concentrations of tezepelumab using noncompartmental methods and the linear/log trapezoidal method. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.
Time frame: Day 1 predose, 0.25, 0.5, and 1 hour after start of infusion (for IV cohorts only), 4, 8, 24, 48, 72 hours postdose and days 5, 6, 7, 11, 15, 22, 29, 43, 57, 71, 85, and (for cohorts who received 420 mg tezepelumab SC or any IV dose) 113.
Part A: Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCinf) of Tezepelumab
The PK parameter AUCinf was estimated based on the serum concentrations of tezepelumab using noncompartmental methods and the linear/log trapezoidal method. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.
Time frame: Day 1 predose, 0.25, 0.5, and 1 hour after start of infusion (for IV cohorts only), 4, 8, 24, 48, 72 hours postdose and days 5, 6, 7, 11, 15, 22, 29, 43, 57, 71, 85, and (for cohorts who received 420 mg tezepelumab SC or any IV dose) 113.
Part A: Elimination Half-life (t1/2) of Tezepelumab
Elimination half-life was estimated based on the serum concentrations of tezepelumab using noncompartmental methods based on the terminal phase of the concentration-time profile. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.
Time frame: Day 1 predose, 0.25, 0.5, and 1 hour after start of infusion (for IV cohorts only), 4, 8, 24, 48, 72 hours postdose and days 5, 6, 7, 11, 15, 22, 29, 43, 57, 71, 85, and (for cohorts who received 420 mg tezepelumab SC or any IV dose) 113.
Part B: Time of Maximum Observed Concentration (Tmax) of Tezepelumab
Tmax was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.
Time frame: Day 1 predose, 0.25, 0.5, 1, 4, 8, 72 hours postdose and days, 7, 15, 22, 29, 43, 57, 71, 85, and 113.
Part B: Maximum Observed Concentration (Cmax) of Tezepelumab
Cmax was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.
Time frame: Day 1 predose, 0.25, 0.5, 1, 4, 8, 72 hours postdose and days, 7, 15, 22, 29, 43, 57, 71, 85, and 113.
Part B: Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Tezepelumab
The PK parameter AUC0-t was estimated based on the serum concentrations of tezepelumab using noncompartmental methods and the linear/log trapezoidal method. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.
Time frame: Day 1 predose, 0.25, 0.5, 1, 4, 8, 72 hours postdose and days, 7, 15, 22, 29, 43, 57, 71, 85, and 113.
Part B: Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCinf) of Tezepelumab
The PK parameter AUCinf was estimated based on the serum concentrations of tezepelumab using noncompartmental methods and the linear/log trapezoidal method. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.
Time frame: Day 1 predose, 0.25, 0.5, 1, 4, 8, 72 hours postdose and days, 7, 15, 22, 29, 43, 57, 71, 85, and 113.
Part B: Elimination Half-life (t1/2) of Tezepelumab
Elimination half-life was estimated based on the serum concentrations of tezepelumab using noncompartmental methods based on the terminal phase of the concentration-time profile. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.
Time frame: Day 1 predose, 0.25, 0.5, 1, 4, 8, 72 hours postdose and days, 7, 15, 22, 29, 43, 57, 71, 85, and 113.
Part B: Percentage of Participants Achieving at Least a 50% Reduction From Baseline in Eczema Area and Severity Index (EASI 50) Score
EASI is a tool used to measure the severity of AD. The index involves an assessment of the average intensity of 4 clinical signs (erythema, infiltration/papulation, excoriations, and lichenification) at 4 body areas (head/neck, upper extremities, trunk, lower extremities) assessed on a scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe. The percent of affected area for each of the 4 body areas is also assessed using the following 6-point scale: 0 = 0%, 1 = \< 10%, 2 =10% to 29%, 3 = 30% to 49%, 4 = 50% to 69%, 5 = 70% to 89%, 6 = 90% to 100%. The total score for each body region is obtained by multiplying the sum of the severity scores of the 4 clinical signs by the area score, with adjustment for the proportion of the body region to the whole body. The sum of the scores for each body region gives the total EASI score, which ranges from 0 to 72, with higher scores indicating greater disease severity.
Time frame: Baseline and days 15, 29, 43, 57, 85, and 113
Part B: Percentage of Participants Achieving at Least a 75% Reduction From Baseline in Eczema Area and Severity Index (EASI 75) Score
EASI is a tool used to measure the severity of AD. The index involves an assessment of the average intensity of 4 clinical signs (erythema, infiltration/papulation, excoriations, and lichenification) at 4 body areas (head/neck, upper extremities, trunk, lower extremities) assessed on a scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe. The percent of affected area for each of the 4 body areas is also assessed using the following 6-point scale: 0 = 0%, 1 = \< 10%, 2 =10% to 29%, 3 = 30% to 49%, 4 = 50% to 69%, 5 = 70% to 89%, 6 = 90% to 100%. The total score for each body region is obtained by multiplying the sum of the severity scores of the 4 clinical signs by the area score, with adjustment for the proportion of the body region to the whole body. The sum of the scores for each body region gives the total EASI score, which ranges from 0 to 72, with higher scores indicating greater disease severity.
Time frame: Baseline and days 15, 29, 43, 57, 85, and 113
Part B: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score
EASI is a tool used to measure the severity of AD. The index involves an assessment of the intensity of 4 clinical signs (erythema, infiltration/papulation, excoriations, and lichenification) at 4 body areas (head/neck, upper extremities, trunk, lower extremities) assessed on a scale from 0 (none) to 3 (severe). The percent affected area for each of the 4 body areas is assessed on a 6-point scale from 0 (0%) to 6 (90% to 100%). The total score for each body region is obtained by multiplying the sum of the severity scores of the 4 clinical signs by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score is the sum of the scores for each body region, and ranges from 0 to 72, with higher scores indicating greater disease severity. Percent change from baseline = \[(Post-baseline Value - Baseline Value) / Baseline Value\] x 100. A negative change from baseline indicates improvement.
Time frame: Baseline and days 15, 29, 43, 57, 85, and 113
Part B: Change From Baseline in Investigator's Global Assessment (IGA)
IGA score is a static 6-point measure of disease activity based on an overall assessment of skin lesions. The IGA was scored on a scale of 0 to 5, where 0 (clear) = no inflammatory signs of AD; 1. (almost clear) = just perceptible erythema and just perceptible papulation/infiltration; 2. (mild) = mild erythema and mild papulation and infiltration; 3. (moderate) = moderate erythema and moderate papulation and infiltration; 4. (severe) = severe disease with severe erythema and severe papulation and infiltration; 5. (very severe) = severe disease with severe erythema and severe papulation and infiltration with oozing/crusting. A negative change from baseline indicates improvement.
Time frame: Baseline and days 15, 29, 43, 57, 85, and 113
This study was a single-ascending dose (SAD) study of tezepelumab in healthy adults (Part A; Cohorts 1-8) and adults with moderate to severe atopic dermatitis (AD) (Part B; Cohort 9). The study was conducted at seven centers in the United States, including one center that conducted the testing in all healthy adults and six centers that performed the study in AD participants. Dose escalation was based on blinded review of safety data up to day 15 from the previous cohort.
| Milestone | Part A: Tezepelumab 2.1 mg SC | Part A: Tezepelumab 7 mg SC | Part A: Tezepelumab 21 mg SC | Part A: Tezepelumab 70 mg SC | Part A: Tezepelumab 210 mg SC | Part A: Tezepelumab 420 mg SC | Part A: Tezepelumab 210 mg IV | Part A: Tezepelumab 700 mg IV | Part A: Placebo | Part B: Tezepelumab 700 mg IV | Part B: Placebo IV |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 16 | 10 | 4 |
| Received study drug | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 16 | 9 | 3 |
| Completed | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 15 | 9 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Ineligibility determined | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Adverse events (AEs) include any untoward medical occurrence in a trial participant administered a study drug and does not necessarily have a causal relationship with this treatment. AEs include worsening of a pre-existing medical condition and laboratory value changes requiring therapy or adjustment in prior therapy. AEs were assessed for severity according to the Common Terminology Criteria for Adverse Events (CTCAE), Version 3, where Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = severe AE, Grade 4 = life-threatening AE and Grade 5 = death due to AE. Relationship to study treatment was determined by the investigator. A serious adverse event (SAE) is defined as an AE that met 1 or more of below criteria: * was fatal; * was life threatening; * required in-patient hospitalization or prolongation of existing hospitalization; * resulted in persistent or significant disability/incapacity; * was a congenital anomaly/birth defect; * other significant medical hazard.
| Participants | Part A: Tezepelumab 2.1 mg SC | Part A: Tezepelumab 7 mg SC | Part A: Tezepelumab 21 mg SC | Part A: Tezepelumab 70 mg SC | Part A: Tezepelumab 210 mg SC | Part A: Tezepelumab 420 mg SC | Part A: Tezepelumab 210 mg IV | Part A: Tezepelumab 700 mg IV | Part A: Placebo SC | Part A: Placebo IV | Part B: Tezepelumab 700 mg IV | Part B: Placebo IV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any adverse event | 3 | 5 | 1 | 6 | 2 | 3 | 4 | 5 | 8 | 3 | 7 | 3 |
| Serious adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| AE leading to study drug discontinuation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AE leading to discontinuation from study | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fatal adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Treatment-related adverse event | 1 | 0 | 0 | 0 | 2 | 1 | 2 | 0 | 4 | 1 | 3 | 3 |
The time at which the maximum concentration of tezepelumab was observed was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification of the assay was 10 ng/mL.
| hours | Part A: Tezepelumab 2.1 mg SC | Part A: Tezepelumab 7 mg SC | Part A: Tezepelumab 21 mg SC | Part A: Tezepelumab 70 mg SC | Part A: Tezepelumab 210 mg SC | Part A: Tezepelumab 420 mg SC | Part A: Tezepelumab 210 mg IV | Part A: Tezepelumab 700 mg IV |
|---|---|---|---|---|---|---|---|---|
| Part A: Time of Maximum Observed Concentration (Tmax) of Tezepelumab | 190.94 (117.87 to 332.15) | 237.09 (140.50 to 335.07) | 142.10 (117.43 to 336.10) | 130.87 (69.27 to 237.90) | 93.65 (70.22 to 359.17) | 80.89 (68.27 to 116.58) | 1.13 (1.08 to 8.00) | 1.04 (1.02 to 1.17) |
All study samples (tezepelumab and placebo) were tested using an electrochemiluminescence (ECL) based immunoassay to detect and confirm the presence of antibodies capable of binding to tezepelumab. Samples identified as positive in the immunoassay were tested in a receptor-binding ECL-based assay to detect neutralizing or inhibitory effects toward tezepelumab. The number of participants with positive anti-tezepelumab binding antibodies / neutralizing antibodies at any time post-baseline with a negative or no result at baseline is reported.
| Participants | Part A: Tezepelumab 2.1 mg SC | Part A: Tezepelumab 7 mg SC | Part A: Tezepelumab 21 mg SC | Part A: Tezepelumab 70 mg SC | Part A: Tezepelumab 210 mg SC | Part A: Tezepelumab 420 mg SC | Part A: Tezepelumab 210 mg IV | Part A: Tezepelumab 700 mg IV | Part A: Placebo | Part B: Tezepelumab 700 mg IV | Part B: Placebo IV |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-tezepelumab binding antibodies | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Anti-tezepelumab neutralizing antibodies | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The maximum observed serum concentration of tezepelumab was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification of the assay was 10 ng/mL.
| μg/mL | Part A: Tezepelumab 2.1 mg SC | Part A: Tezepelumab 7 mg SC | Part A: Tezepelumab 21 mg SC | Part A: Tezepelumab 70 mg SC | Part A: Tezepelumab 210 mg SC | Part A: Tezepelumab 420 mg SC | Part A: Tezepelumab 210 mg IV | Part A: Tezepelumab 700 mg IV |
|---|---|---|---|---|---|---|---|---|
| Part A: Maximum Observed Concentration (Cmax) of Tezepelumab | 0.257 ± 0.0824 | 0.792 ± 0.0593 | 2.01 ± 0.620 | 7.82 ± 2.25 | 23.6 ± 10.3 | 58.0 ± 19.3 | 64.4 ± 10.2 | 219 ± 38.3 |
The PK parameter AUC0-t was estimated based on the serum concentrations of tezepelumab using noncompartmental methods and the linear/log trapezoidal method. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.
| day*μg/mL | Part A: Tezepelumab 2.1 mg SC | Part A: Tezepelumab 7 mg SC | Part A: Tezepelumab 21 mg SC | Part A: Tezepelumab 70 mg SC | Part A: Tezepelumab 210 mg SC | Part A: Tezepelumab 420 mg SC | Part A: Tezepelumab 210 mg IV | Part A: Tezepelumab 700 mg IV |
|---|---|---|---|---|---|---|---|---|
| Part A: Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Tezepelumab | 8.12 ± 1.96 | 32.9 ± 2.75 | 76.7 ± 31.6 | 278 ± 64.3 | 867 ± 349 | 2050 ± 627 | 1150 ± 176 | 3440 ± 253 |
The PK parameter AUCinf was estimated based on the serum concentrations of tezepelumab using noncompartmental methods and the linear/log trapezoidal method. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.
| day*μg/mL | Part A: Tezepelumab 2.1 mg SC | Part A: Tezepelumab 7 mg SC | Part A: Tezepelumab 21 mg SC | Part A: Tezepelumab 70 mg SC | Part A: Tezepelumab 210 mg SC | Part A: Tezepelumab 420 mg SC | Part A: Tezepelumab 210 mg IV | Part A: Tezepelumab 700 mg IV |
|---|---|---|---|---|---|---|---|---|
| Part A: Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCinf) of Tezepelumab | 8.69 ± 1.97 | 36.6 ± 4.60 | 84.6 ± 37.9 | 303 ± 70.3 | 976 ± 409 | 2140 ± 677 | 1200 ± 208 | 3530 ± 322 |
Elimination half-life was estimated based on the serum concentrations of tezepelumab using noncompartmental methods based on the terminal phase of the concentration-time profile. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.
| days | Part A: Tezepelumab 2.1 mg SC | Part A: Tezepelumab 7 mg SC | Part A: Tezepelumab 21 mg SC | Part A: Tezepelumab 70 mg SC | Part A: Tezepelumab 210 mg SC | Part A: Tezepelumab 420 mg SC | Part A: Tezepelumab 210 mg IV | Part A: Tezepelumab 700 mg IV |
|---|---|---|---|---|---|---|---|---|
| Part A: Elimination Half-life (t1/2) of Tezepelumab | 19.9 ± 4.81 | 23.4 ± 4.30 | 22.7 ± 4.81 | 22.5 ± 1.35 | 25.7 ± 5.52 | 23.3 ± 2.89 | 24.5 ± 6.28 | 20.7 ± 6.44 |
Tmax was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.
| hours | Part B: Tezepelumab 700 mg IV |
|---|---|
| Part B: Time of Maximum Observed Concentration (Tmax) of Tezepelumab | 4.08 (1.00 to 8.12) |
Cmax was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.
| μg/mL | Part B: Tezepelumab 700 mg IV |
|---|---|
| Part B: Maximum Observed Concentration (Cmax) of Tezepelumab | 253 ± 57.2 |
The PK parameter AUC0-t was estimated based on the serum concentrations of tezepelumab using noncompartmental methods and the linear/log trapezoidal method. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.
| day*μg/mL | Part B: Tezepelumab 700 mg IV |
|---|---|
| Part B: Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Tezepelumab | 3660 ± 990 |
The PK parameter AUCinf was estimated based on the serum concentrations of tezepelumab using noncompartmental methods and the linear/log trapezoidal method. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.
| day*μg/mL | Part B: Tezepelumab 700 mg IV |
|---|---|
| Part B: Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCinf) of Tezepelumab | 3830 ± 1230 |
Elimination half-life was estimated based on the serum concentrations of tezepelumab using noncompartmental methods based on the terminal phase of the concentration-time profile. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.
| days | Part B: Tezepelumab 700 mg IV |
|---|---|
| Part B: Elimination Half-life (t1/2) of Tezepelumab | 22.2 ± 4.72 |
EASI is a tool used to measure the severity of AD. The index involves an assessment of the average intensity of 4 clinical signs (erythema, infiltration/papulation, excoriations, and lichenification) at 4 body areas (head/neck, upper extremities, trunk, lower extremities) assessed on a scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe. The percent of affected area for each of the 4 body areas is also assessed using the following 6-point scale: 0 = 0%, 1 = \< 10%, 2 =10% to 29%, 3 = 30% to 49%, 4 = 50% to 69%, 5 = 70% to 89%, 6 = 90% to 100%. The total score for each body region is obtained by multiplying the sum of the severity scores of the 4 clinical signs by the area score, with adjustment for the proportion of the body region to the whole body. The sum of the scores for each body region gives the total EASI score, which ranges from 0 to 72, with higher scores indicating greater disease severity.
| percentage of participants | Part B: Tezepelumab 700 mg IV | Part B: Placebo |
|---|---|---|
| Day 15 | 22 | 0 |
| Day 29 | 22 | 0 |
| Day 43 | 22 | 33 |
| Day 57 | 22 | 0 |
| Day 85 | 50 | 0 |
| Day 113 | 33 | 33 |
| At any postdose time point | 56 | 33 |
EASI is a tool used to measure the severity of AD. The index involves an assessment of the average intensity of 4 clinical signs (erythema, infiltration/papulation, excoriations, and lichenification) at 4 body areas (head/neck, upper extremities, trunk, lower extremities) assessed on a scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe. The percent of affected area for each of the 4 body areas is also assessed using the following 6-point scale: 0 = 0%, 1 = \< 10%, 2 =10% to 29%, 3 = 30% to 49%, 4 = 50% to 69%, 5 = 70% to 89%, 6 = 90% to 100%. The total score for each body region is obtained by multiplying the sum of the severity scores of the 4 clinical signs by the area score, with adjustment for the proportion of the body region to the whole body. The sum of the scores for each body region gives the total EASI score, which ranges from 0 to 72, with higher scores indicating greater disease severity.
| percentage of participants | Part B: Tezepelumab 700 mg IV | Part B: Placebo |
|---|---|---|
| Day 15 | 0 | 0 |
| Day 29 | 0 | 0 |
| Day 43 | 0 | 0 |
| Day 57 | 11 | 0 |
| Day 85 | 13 | 0 |
| Day 113 | 22 | 0 |
| At any postdose time point | 22 | 0 |
EASI is a tool used to measure the severity of AD. The index involves an assessment of the intensity of 4 clinical signs (erythema, infiltration/papulation, excoriations, and lichenification) at 4 body areas (head/neck, upper extremities, trunk, lower extremities) assessed on a scale from 0 (none) to 3 (severe). The percent affected area for each of the 4 body areas is assessed on a 6-point scale from 0 (0%) to 6 (90% to 100%). The total score for each body region is obtained by multiplying the sum of the severity scores of the 4 clinical signs by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score is the sum of the scores for each body region, and ranges from 0 to 72, with higher scores indicating greater disease severity. Percent change from baseline = \[(Post-baseline Value - Baseline Value) / Baseline Value\] x 100. A negative change from baseline indicates improvement.
| percent change | Part B: Tezepelumab 700 mg IV | Part B: Placebo |
|---|---|---|
| Day 15 | -12.47 ± 43.32 | 15.10 ± 55.84 |
| Day 29 | -23.61 ± 32.82 | -25.03 ± 20.38 |
| Day 43 | -17.04 ± 44.28 | -32.41 ± 31.81 |
| Day 57 | -22.83 ± 41.23 | -1.89 ± 37.24 |
| Day 85 | -31.70 ± 42.14 | -23.01 ± 21.16 |
| Day 113 | -25.25 ± 49.40 | -11.28 ± 54.63 |
IGA score is a static 6-point measure of disease activity based on an overall assessment of skin lesions. The IGA was scored on a scale of 0 to 5, where 0 (clear) = no inflammatory signs of AD; 1. (almost clear) = just perceptible erythema and just perceptible papulation/infiltration; 2. (mild) = mild erythema and mild papulation and infiltration; 3. (moderate) = moderate erythema and moderate papulation and infiltration; 4. (severe) = severe disease with severe erythema and severe papulation and infiltration; 5. (very severe) = severe disease with severe erythema and severe papulation and infiltration with oozing/crusting. A negative change from baseline indicates improvement.
| scores on a scale | Part B: Tezepelumab 700 mg IV | Part B: Placebo |
|---|---|---|
| Day 15 | -0.33 ± 0.50 | 0.33 ± 0.58 |
| Day 29 | -0.56 ± 0.73 | -0.67 ± 0.58 |
| Day 43 | -0.44 ± 0.53 | -1.00 ± 0.00 |
| Day 57 | -0.44 ± 0.73 | -1.00 ± 0.00 |
| Day 85 | -0.63 ± 0.74 | -1.33 ± 0.58 |
| Day 113 | -0.44 ± 0.73 | -0.33 ± 1.15 |
Collected over For Part A Tezepelumab/Placebo 2.1 mg, 7 mg, 21 mg, 70 mg, and 210 mg SC: 85 days. For Part A Tezepelumab/Placebo 420 mg SC, 210 mg IV, and 700 mg IV and Part B: 113 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Tezepelumab 2.1 mg SC | — | 0/6 (0%) | 3/6 (50%) |
| Part A: Tezepelumab 7 mg SC | — | 0/6 (0%) | 5/6 (83.3%) |
| Part A: Tezepelumab 21 mg SC | — | 0/6 (0%) | 1/6 (16.7%) |
| Part A: Tezepelumab 70 mg SC | — | 0/6 (0%) | 6/6 (100%) |
| Part A: Tezepelumab 210 mg SC | — | 0/6 (0%) | 2/6 (33.3%) |
| Part A: Tezepelumab 420 mg SC | — | 0/6 (0%) | 3/6 (50%) |
| Part A: Tezepelumab 210 mg IV | — | 0/6 (0%) | 4/6 (66.7%) |
| Part A: Tezepelumab 700 mg IV | — | 0/6 (0%) | 5/6 (83.3%) |
| Part A: Placebo SC | — | 0/12 (0%) | 8/12 (66.7%) |
| Part A: Placebo IV | — | 0/4 (0%) | 3/4 (75%) |
| Part B: Tezepelumab 700 mg IV | — | 0/9 (0%) | 7/9 (77.8%) |
| Part B: Placebo IV | — | 1/3 (33.3%) | 3/3 (100%) |
| Event | Part A: Tezepelumab 2.1 mg SC | Part A: Tezepelumab 7 mg SC | Part A: Tezepelumab 21 mg SC | Part A: Tezepelumab 70 mg SC | Part A: Tezepelumab 210 mg SC | Part A: Tezepelumab 420 mg SC | Part A: Tezepelumab 210 mg IV | Part A: Tezepelumab 700 mg IV | Part A: Placebo SC | Part A: Placebo IV | Part B: Tezepelumab 700 mg IV | Part B: Placebo IV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INFECTIONInfections and infestations | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/4 | 0/9 | 1/3 |
| PROCEDURAL PAINInjury, poisoning and procedural complications | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/4 | 0/9 | 1/3 |
| Event | Part A: Tezepelumab 2.1 mg SC | Part A: Tezepelumab 7 mg SC | Part A: Tezepelumab 21 mg SC | Part A: Tezepelumab 70 mg SC | Part A: Tezepelumab 210 mg SC | Part A: Tezepelumab 420 mg SC | Part A: Tezepelumab 210 mg IV | Part A: Tezepelumab 700 mg IV | Part A: Placebo SC | Part A: Placebo IV | Part B: Tezepelumab 700 mg IV | Part B: Placebo IV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INSOMNIAPsychiatric disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/12 | 0/4 | 1/9 | 2/3 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 0/6 | 2/6 | 0/6 | 3/6 | 0/6 | 0/6 | 1/6 | 1/6 | 4/12 | 1/4 | 2/9 | 1/3 |
| HEADACHENervous system disorders | 1/6 | 2/6 | 0/6 | 3/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/12 | 1/4 | 0/9 | 0/3 |
| CONJUNCTIVITISEye disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/4 | 0/9 | 1/3 |
| ANIMAL BITEInjury, poisoning and procedural complications | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/4 | 0/9 | 1/3 |
| JOINT INJURYInjury, poisoning and procedural complications | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/4 | 0/9 | 1/3 |
| POST PROCEDURAL COMPLICATIONInjury, poisoning and procedural complications | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/4 | 0/9 | 1/3 |
| MYALGIAMusculoskeletal and connective tissue disorders | 1/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 2/6 | 0/6 | 0/12 | 0/4 | 0/9 | 0/3 |
| DIZZINESSNervous system disorders | 0/6 | 0/6 | 0/6 | 1/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/4 | 0/9 | 1/3 |
| LIBIDO DECREASEDPsychiatric disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/4 | 0/9 | 1/3 |
Participants who received at least 1 dose of Investigational product.
| Age, Continuous(years) | Part A: Tezepelumab 2.1 mg SC | Part A: Tezepelumab 7 mg SC | Part A: Tezepelumab 21 mg SC | Part A: Tezepelumab 70 mg SC | Part A: Tezepelumab 210 mg SC | Part A: Tezepelumab 420 mg SC | Part A: Tezepelumab 210 mg IV | Part A: Tezepelumab 700 mg IV | Part A: Placebo | Part B: Tezepelumab 700 mg IV | Part B: Placebo IV | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 28.2 ± 4.9 | 32.2 ± 2.1 | 36.8 ± 2.6 | 28.3 ± 4.9 | 33.7 ± 4.1 | 37.0 ± 3.7 | 33.0 ± 7.5 | 30.2 ± 3.6 | 32.3 ± 7.6 | 48.1 ± 11.3 | 45.3 ± 5.5 | 34.8 ± 8.6 |
| Sex: Female, Male(Participants) | Part A: Tezepelumab 2.1 mg SC | Part A: Tezepelumab 7 mg SC | Part A: Tezepelumab 21 mg SC | Part A: Tezepelumab 70 mg SC | Part A: Tezepelumab 210 mg SC | Part A: Tezepelumab 420 mg SC | Part A: Tezepelumab 210 mg IV | Part A: Tezepelumab 700 mg IV | Part A: Placebo | Part B: Tezepelumab 700 mg IV | Part B: Placebo IV | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 2 | 5 | 1 | 0 | 0 | 1 | 1 | 3 | 2 | 0 | 16 |
| Male | 5 | 4 | 1 | 5 | 6 | 6 | 5 | 5 | 13 | 7 | 3 | 60 |
| Race/Ethnicity, Customized(Participants) | Part A: Tezepelumab 2.1 mg SC | Part A: Tezepelumab 7 mg SC | Part A: Tezepelumab 21 mg SC | Part A: Tezepelumab 70 mg SC | Part A: Tezepelumab 210 mg SC | Part A: Tezepelumab 420 mg SC | Part A: Tezepelumab 210 mg IV | Part A: Tezepelumab 700 mg IV | Part A: Placebo | Part B: Tezepelumab 700 mg IV | Part B: Placebo IV | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| White | 1 | 1 | 0 | 2 | 3 | 2 | 2 | 2 | 4 | 8 | 2 | 27 |
| Black or African American | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 0 | 1 | 7 |
| Hispanic or Latino | 3 | 5 | 5 | 4 | 2 | 2 | 4 | 1 | 11 | 0 | 0 | 37 |
| Asian | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 3 |
| Other | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 2 |
No study locations are listed for this record.
Ran from Sep 2008 to primary completion in Jan 2011, 27 months.
Results were first posted in Jul 2022, 11 years 6 months after primary completion.
Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 27 months is above that.
Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tezepelumab